Focusing on the Development of Oligonucleotide Therapeutics,
Benefiting Mankind Through the Power of Innovation

siRNA drug company with leading platform

Argo Biopharma is a clinical stage biotech company that committed to developing a new generation of siRNA drugs to provide better treatments for global patients.

Learn More
  • 2021

    Company Established
  • Over US $100 M

    Closed Financing
  • 70 +

    Company Members
  • 29

    PCT Patent Submitted
  • 30 +

    Pipelines
  • 5

    5 clinical stage

Partnering

With its cutting-edge siRNA platform technology, RADS, Argo Biopharma is able to provide Best-In-Class candidates for a range of indications.
Argo's extensive pipeline encompasses a wide range of therapeutic areas, including cardiovascular, metabolic disorders, hematological, CNS, hepatitis, and complement mediated diseases. We recognize that collaborating with other organizations can expedite the advancement of our novel medications towards clinical trials and eventual commercialization. To expand our wide pipelines, we are open to out-licensing, asset acquisitions, and strategic partnerships.

Learn More

Latest News

All News
May. 07, 2024

First Patient Dosed in Phase 2 Clinical Trial of Argo Biopharma BW-01, a Novel siRNA Drug for the Treatment of Severe Hypertriglyceridemia

Learn More

Copyright © 2023 Argo Biopharma. All rights reserved.

Privacy Policy | Site Map

为了更好的呈现效果,移动端请竖屏浏览